NMD4C Launch Canadian Neuromuscular Clinical Trial Network

The Neuromuscular Disease Network for Canada is thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work. Led by investigators Dr. Craig Campbell, Dr. Jean Mah, and Dr. Kerri Schellenberg, the CTN will work towards increasing the number of neuromuscular clinical trials conducted in Canada, enhancing Canadian neuromuscular trial capacity, and supporting a cohesive network of clinician researchers and their teams.  

Increasing the number of neuromuscular clinical trials conducted in Canada 

The CTN will facilitate connections between industry and clinical sites to support the activation of new clinical trials or the opening of new clinical trial sites. We will deliver information about upcoming neuromuscular trial opportunities and offer information on existing trials available and implement strategic promotion to increase international visibility of the benefits of conducting neuromuscular clinical trials in Canada. 

Enhancing trial capacity 

The CTN will offer education and training programs to clinicians and their teams to improve clinical trial execution, connect with existing patient organizations to increase opportunities for patients to participate in neuromuscular clinical trials, and gather patient feedback from patient organizations and clinical sites to advance the development of patient-centric clinical trials. 

Supporting a network of clinician researchers and their teams 

The CTN will facilitate peer-to-peer mentorship opportunities among trialists specializing in neuromuscular clinical trials, coordinate a pan-Canadian hub for trialists and their teams to discuss clinical trial experiences, and launch a Canada-wide community of practice program for clinical trial coordinators overseeing neuromuscular clinical trials. 

The CTN leadership group will be supported by Maria Masnata, our new clinical trials and community of practice manager. Learn more about the CTN mission and objectives, or contact Maria Masnata for more information! 

NMD4C logo with text reading 'Canadian neuromuscular clinical trials network', MDC and IMHA logos at bottom.

Read next...

2024 NMD4C Annual Meeting

NMD4C Welcomed Investigators to Annual Meeting in Calgary

Thank you to our investigators who attended the Annual NMD4C Meeting on September 27th in Calgary! Our meeting program consisted of presentations from pillar and task leads which highlighted their groups’ achievements and progress made to date.

LEARNMD logo

NMD4C Launch Educational Platform LEARNMD

LEARNMD is an online educational platform offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide.

CNDR logo4x3

October 2024 Updates from the Canadian Neuromuscular Disease Registry

The Canadian Neuromuscular Disease Registry (CNDR) is pleased to share updates on several exciting initiatives this fall!

2025 early career awards

2025 Annual NMD4C Early-Career Awards Open for Applications

We are excited to announce the opening of our third annual early-career awards competition!

Canadian neuromuscular fellows attend the WCNMC in Calgary, AB.

NMD4C Provides Opportunity for Neuromuscular Fellows to Build Clinical Network at National Meeting

We are pleased to share that this fall we provided an opportunity for clinical neuromuscular fellows to attend NMD4C’s annual meeting and the Western Canadian Neuromuscular Conference (WCNMC) in Calgary.

newborn screening

NMD4C Investigators Submit Response to CDA Draft Guidance on NBS

A group of NMD4C investigators recently submitted a response to the discussion paper from Canada’s Drug Agency outlining its approach for developing Canadian newborn screening guidance.